Silo Pharma Inc (NASDAQ:SILO) — Market Cap & Net Worth
Market Cap & Net Worth: Silo Pharma Inc (SILO)
Silo Pharma Inc (NASDAQ:SILO) has a market capitalization of $4.80 Million ($4.80 Million) as of July 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28633 globally and #5790 in its home market, demonstrating a -7.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Silo Pharma Inc's stock price $4.25 by its total outstanding shares 1128610 (1.13 Million). Review cash generation quality of Silo Pharma Inc to assess how much free cash flow the company generates relative to operating cash flow.
Silo Pharma Inc Market Cap History: 2026 to 2026
Silo Pharma Inc's market capitalization history from 2026 to 2026. Data shows growth from $4.80 Million to $4.80 Million (0.00% CAGR).
Silo Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Silo Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SILO by Market Capitalization
Companies near Silo Pharma Inc in the global market cap rankings as of July 31, 2026.
Key companies related to Silo Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #537 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #556 globally with a market cap of $47.90 Billion USD ( ₩70.69 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $481.70 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $738.34 |
| #537 | Argen-X | BR:ARGX | $49.55 Billion | €746.60 |
| #556 | Samsung Biologics Co Ltd | KO:207940 | $47.90 Billion | ₩1527000.00 |
Silo Pharma Inc Historical Marketcap From 2026 to 2026
Between 2026 and today, Silo Pharma Inc's market cap moved from $4.80 Million to $ 4.80 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.80 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Silo Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.80 Million USD |
| MoneyControl | $4.80 Million USD |
| MarketWatch | $4.80 Million USD |
| marketcap.company | $4.80 Million USD |
| Reuters | $4.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's … Read more